NCT Number: NCT00153114
PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children
Assess the safety and efficacy of polyethyleneglycol3350 laxative as compared to placebo therapy in pediatric patients with a history of constipation.
Looking for future studies?
Notify MeKey information
Conditions
Age range
4 year–16 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Boston, Massachusetts, United States
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female outpatients between the ages of 4 to 16 years.
- Adolescent female patients must not be pregnant or lactating.
- constipated according to ROME I definition
- Two or fewer bowel movements during the initial observation week.
- Absence of a stool impaction
- Bowel movement after receiving enema
- Are otherwise in good health, as judged by a physical examination.
- Parent or guardian is mentally competent to sign an instrument of informed consent
Exclusion criteria
- Patients with heme positive stool at baseline exam.
- Patients with fecal impaction at baseline, or after the observation period, as indicated by physical exam
- Patients with known or suspected perforation or obstruction other than fecal impaction.
- Patients who are breastfeeding, pregnant or intend to become pregnant during the study.
- Female patients of childbearing potential who refuse a pregnancy test.
- Patients with a known history of organic cause for their constipation.
- Patients with congenital malformations that produce constipation (Hirschsprung's disease, imperforate anus, children with cerebral palsy or other neurologic abnormalities, or systemic diseases).
- History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.
- Use of concomitant medications that cause constipation
- Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Patients with known allergy to polyethyleneglycol or polyethyleneglycol containing medications.
- Patients with clinically significant elevations of TSH or abnormal plasma electrolytes.
- Patients who, within the past 30 days have participated in an investigational clinical study
Treatment and study plan
Primary outcomes
-
Greater than 2 bowel movements per week
Secondary outcomes
-
Analysis of individual ROME I criteria
-
Safety (adverse event and laboratory testing)
Sponsors and collaborators
Lead sponsor
Braintree Laboratories
Industry
Registry information
Important dates
- Study start
- 2003
- Primary completion
- 2004
- First posted
- Sep 12, 2005
- Registry last updated
- Feb 7, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Development of a Constipation Risk Assessment Scale for Hospitalized Patients.
NCT04068415
Constipation, Pathological Conditions, Signs and Symptoms
View Trial DetailsMOWOOT Device Treatment for Adults With Chronic Constipation
NCT04666155
Constipation, Constipation - Functional
Durham, County Durham and Darlington, United Kingdom
View Trial DetailsDairy Products to Your Gut and Brain
NCT06311097
Constipation, Healthy
Copenhagen, Denmark
View Trial DetailsRadicle GI Health RDH™: A Study Assessing the Impact of Health and Wellness Products on Gastrointestinal (GI) Health and Related Health Outcomes
NCT07230821
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Del Mar, California, United States
View Trial Details